Your browser doesn't support javascript.
loading
Loss of function of ENT3 drives histiocytosis and inflammation through TLR-MAPK signaling.
Shiloh, Ruth; Lubin, Ruth; David, Odeya; Geron, Ifat; Okon, Elimelech; Hazan, Idit; Zaliova, Marketa; Amarilyo, Gil; Birger, Yehudit; Borovitz, Yael; Brik, Dafna; Broides, Arnon; Cohen-Kedar, Sarit; Harel, Liora; Kristal, Eyal; Kozlova, Daria; Ling, Galina; Shapira Rootman, Mika; Shefer Averbuch, Noa; Spielman, Shiri; Trka, Jan; Izraeli, Shai; Yona, Simon; Elitzur, Sarah.
Afiliação
  • Shiloh R; The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Lubin R; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
  • David O; The Institute of Biomedical and Oral Research, Hebrew University, Jerusalem, Israel.
  • Geron I; Pediatric Endocrinology Unit, Soroka University Medical Center, Beer Sheva, Israel.
  • Okon E; Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
  • Hazan I; Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
  • Zaliova M; The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Amarilyo G; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
  • Birger Y; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Borovitz Y; The Institute of Biomedical and Oral Research, Hebrew University, Jerusalem, Israel.
  • Brik D; Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine of Charles University Prague and University Hospital Motol, Prague, Czech Republic.
  • Broides A; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Cohen-Kedar S; Pediatric Rheumatology Unit, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Harel L; The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Kristal E; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
  • Kozlova D; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ling G; Institute of Nephrology, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Shapira Rootman M; The Rina Zaizov Division of Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Shefer Averbuch N; Pediatric Ambulatory Center, Soroka University Medical Center, Beer Sheva, Israel.
  • Spielman S; Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
  • Trka J; Pediatric Immunology Clinic, Soroka University Medical Center, Beer Sheva, Israel.
  • Izraeli S; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel.
  • Yona S; Division of Gastroenterology, Rabin Medical Center, Petach Tikva, Israel.
  • Elitzur S; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Blood ; 142(20): 1740-1751, 2023 11 16.
Article em En | MEDLINE | ID: mdl-37738562
ABSTRACT
Histiocytoses are inflammatory myeloid neoplasms often driven by somatic activating mutations in mitogen-activated protein kinase (MAPK) cascade genes. H syndrome is an inflammatory genetic disorder caused by germ line loss-of-function mutations in SLC29A3, encoding the lysosomal equilibrative nucleoside transporter 3 (ENT3). Patients with H syndrome are predisposed to develop histiocytosis, yet the mechanism is unclear. Here, through phenotypic, molecular, and functional analysis of primary cells from a cohort of patients with H syndrome, we reveal the molecular pathway leading to histiocytosis and inflammation in this genetic disorder. We show that loss of function of ENT3 activates nucleoside-sensing toll-like receptors (TLR) and downstream MAPK signaling, inducing cytokine secretion and inflammation. Importantly, MEK inhibitor therapy led to resolution of histiocytosis and inflammation in a patient with H syndrome. These results demonstrate a yet-unrecognized link between a defect in a lysosomal transporter and pathological activation of MAPK signaling, establishing a novel pathway leading to histiocytosis and inflammation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histiocitose / Proteínas Quinases Ativadas por Mitógeno Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Histiocitose / Proteínas Quinases Ativadas por Mitógeno Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2023 Tipo de documento: Article